Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …

This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …

Background Savolitinib is a selective MET tyrosine-kinase inhibitor. We investigated the
activity and safety of savolitinib in patients with pulmonary sarcomatoid carcinoma and other …

Roughly 50% of cancer cases occur in people aged 65 years or older. Older people are
often diagnosed at a later stage and might receive less (intensive) treatment, which might …

Lung cancer is the leading cause of cancer death worldwide. In the past decade EGFR, ALK
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …

In the United States, lung cancer is the second most frequently diagnosed type of cancer
and the leading cause of cancer deaths. 1 Non–small-cell lung cancer (NSCLC), which …

Cancer is a major cause of death worldwide. MET tyrosine kinase receptor [MET, c-MET,
hepatocyte growth factor (HGF) receptor] pathway activation is associated with the …

Simple Summary The treatment of advanced and metastatic non-small cell lung cancer
(NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide
and has a poor prognosis. Current treatments for advanced NSCLC included traditional …

Abstract Purpose: Telisotuzumab vedotin (Teliso-V) is an anti–c-Met–directed antibody–drug
conjugate. Here, we present safety and efficacy data from a phase I/Ib study of Teliso-V …